PRD Therapeutics
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10M
Overview
A biotech startup developing the world's first selective SOAT2 inhibitor oral drugs for rare and common lipid metabolism disorders.
Metabolic DiseaseCardiovascular
Technology Platform
Platform based on selective SOAT2 (Sterol O-acyltransferase 2) inhibitors, derived from the natural product pyripyropene A, representing the world's first and only selective SOAT2 inhibition approach.
Opportunities
The massive global prevalence of MASH/MASLD (>30%) represents a multi-billion dollar market opportunity, while the high unmet need in HoFH provides a potential accelerated development pathway.
Risk Factors
Clinical validation of the novel SOAT2 selective mechanism remains unproven in humans, and the company faces significant competition in both dyslipidemia and MASH therapeutic spaces from established pharma companies.
Competitive Landscape
PRD's primary differentiation is selectivity for SOAT2 over SOAT1, avoiding adverse events that doomed previous dual inhibitors; they compete against PCSK9 inhibitors, statins, and emerging MASH therapies from companies like Madrigal, 89bio, and Akero.